MedPath

Phase II clinical study of CIM331 (hemodialysis)

Phase 2
Conditions
Pruritus in dialysis patients
Registration Number
JPRN-jRCT2080222909
Lead Sponsor
CHUGAI PHARMACEUTICAL CO., LTD
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
60
Inclusion Criteria

(1) Patients who receive hemodialysis three times a week.
(2) Patients who have been treated with systemic therapy or topical therapy for pruritus and who are inadequately controlled by them, or patients who have been treated with nalfurafine hydrochloride for pruritus.

Exclusion Criteria

Patients who are judged to be inadequate for this study participation by investigator.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath